Budesonide orodispersible tablet for inducing remission of eosinophilic oesophagitis - guidance (TA708)
NICE recommends budesonide orodispersible tablet (ODT) as an option for inducing remission of eosinophilic oesophagitis in adults based on clinical trial evidence that shows it improves signs and symptoms of eosinophilic oesophagitis vs placebo
Source:
National Institute for Health and Care Excellence
SPS commentary:
Budesonide ODT has a marketing authorisation for both inducing and maintaining remission in eosinophilic oesophagitis; at the time this appraisal started it was only licensed for induction. So, the company's evidence is for inducing remission only (with treatment of up to 12 weeks) and the committee is unable to make recommendations for maintenance treatment.